Previous 10 | Next 10 |
The following slide deck was published by ArQule, Inc. in conjunction with this Read more ...
ArQule, Inc. (Nasdaq: ARQL) today announced that Robert Weiskopf, Senior Vice President, Chief Financial Officer and Treasurer, has decided to retire effective March 29 of this year. In conjunction with Mr. Weiskopf’s departure, ArQule is naming Marc Schegerin, MD as Chief Financial O...
ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Brian Schwartz, MD, Chief Medical Officer and Head of Research and Development, of ArQule will present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 at 10...
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in the 31st Annual ROTH Conference on March 17-19, 2019 in Dana Point, California. About ArQ...
ArQule, Inc. (ARQL) Q4 2018 Earnings Conference Call March 07, 2019, 09:00 AM ET Company Participants Marc Schegerin - SVP of Strategy, Finance and Communications Paolo Pucci - CEO Brian Schwartz - Head of R&D Rob Weiskopf - CFO Conference Call Participants Jonathan C...
Gainers: Bio-Path Holdings (NASDAQ: BPTH ) +201% . Seelos Therapeutics (NASDAQ: SEEL ) +79% . ArQule (NASDAQ: ARQL ) +66% . Altimmune (NASDAQ: ALT ) +60% . Rosetta Stone (NYSE: RST ) +31% . Calumet Specialty Products Partners (NASDAQ: CLMT ) +29% . Cleveland BioLabs (NASDAQ: CB...
ArQule ( ARQL +48.6% ) is up on more than double normal volume in early trade following its Q4 repor t that featured a revenue beat, albeit by only $1.1M, from its licensing deal with Sinovant. More news on: ArQule, Inc., Healthcare stocks news, Stocks on the move, Read more ...
ArQule (NASDAQ: ARQL ): Q4 GAAP EPS of -$0.08 misses by $0.01 . More news on: ArQule, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Conference call scheduled today at 9:00 a.m. ET ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the fourth quarter and full year of 2018. For the quarter ended December 31, 2018, the Company reported a net loss of $8,487,000 or $0.08 per share, compared wit...
ArQule ( ARQL +3.3% ) is up on below-average volume in response to preliminary data on miransertib in patients with Proteus syndrome, an ultra-rare condition characterized by abnormal overgrowth of multiple tissue which changes the shape of body structures over time.The results were just...
News, Short Squeeze, Breakout and More Instantly...
What stock will go up the most in 2020? We'd all like to know that one. And it's a question that's a lot easier to ask than to answer. Let's start by looking at the top 10 stocks of 2019 for clues. The No. 1 stock of 2019, Axsome Therapeutics , had a staggering 3,578% retu...
Dollar Tree (NASDAQ: DLTR) stock was pummeled in November after its earnings report resulted in the deep discounter reducing its sales outlook for the third consecutive quarter and lowering its profit forecast. Shares trade at the same level now as they did a year ago, meaning inves...
The top 10 stocks of 2019 are an interesting group. You might think tech stocks would dominate the upper echelon of equities, but you'd be wrong. As we saw in the IPO market , individual healthcare stocks actually had the strongest returns last year. Seven biotech companies made our list, inc...